1. Home
  2. CALC vs TPCS Comparison

CALC vs TPCS Comparison

Compare CALC & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • TPCS
  • Stock Information
  • Founded
  • CALC 2011
  • TPCS 1956
  • Country
  • CALC United States
  • TPCS United States
  • Employees
  • CALC N/A
  • TPCS N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • TPCS Metal Fabrications
  • Sector
  • CALC Health Care
  • TPCS Industrials
  • Exchange
  • CALC Nasdaq
  • TPCS Nasdaq
  • Market Cap
  • CALC 48.1M
  • TPCS 51.4M
  • IPO Year
  • CALC N/A
  • TPCS N/A
  • Fundamental
  • Price
  • CALC $3.20
  • TPCS $5.44
  • Analyst Decision
  • CALC Strong Buy
  • TPCS
  • Analyst Count
  • CALC 2
  • TPCS 0
  • Target Price
  • CALC $14.50
  • TPCS N/A
  • AVG Volume (30 Days)
  • CALC 73.7K
  • TPCS 59.0K
  • Earning Date
  • CALC 11-12-2025
  • TPCS 08-21-2025
  • Dividend Yield
  • CALC N/A
  • TPCS N/A
  • EPS Growth
  • CALC N/A
  • TPCS N/A
  • EPS
  • CALC N/A
  • TPCS N/A
  • Revenue
  • CALC N/A
  • TPCS $33,424,000.00
  • Revenue This Year
  • CALC N/A
  • TPCS N/A
  • Revenue Next Year
  • CALC N/A
  • TPCS N/A
  • P/E Ratio
  • CALC N/A
  • TPCS N/A
  • Revenue Growth
  • CALC N/A
  • TPCS 3.78
  • 52 Week Low
  • CALC $1.42
  • TPCS $2.05
  • 52 Week High
  • CALC $5.65
  • TPCS $6.25
  • Technical
  • Relative Strength Index (RSI)
  • CALC 54.05
  • TPCS 54.95
  • Support Level
  • CALC $2.62
  • TPCS $5.26
  • Resistance Level
  • CALC $3.73
  • TPCS $5.50
  • Average True Range (ATR)
  • CALC 0.35
  • TPCS 0.26
  • MACD
  • CALC -0.01
  • TPCS -0.04
  • Stochastic Oscillator
  • CALC 52.25
  • TPCS 46.53

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

About TPCS TechPrecision Corporation Common stock

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

Share on Social Networks: